Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (5174)	6/19/1998 11:55:00 PM
From: Miljenko Zuanic	Respond to of 9719

Right Andreas! Classical and good old method, search for undiscovered and cheap promising third-tier bts is no longer characteristic of this board, imo. Corixa is indeed very interesting bt. Vaccines are again hot issue and Corixa has very promising programs. Their anti-Her-2 vaccine presentation at ASCO was side by side with Zeneca and Genentech one. + 2K oncologists reaction surprised me very much. They show not only strong antibody response to specific protein (vaccine constituent), but also strong epitope spread. Now, if only they can deliver that deal with SKB on TB vaccines street will not think twice before they step in. Miljenko PS: I own CRXA